Rapid photoperiod-induced increase in detectable GnRH mRNA-containing cells in Siberian hamster

The American Journal of Physiology
T Porkka-HeiskanenTeresa H Horton

Abstract

To determine whether changes in gonadotropin-releasing hormone (GnRH) neurons are early indicators of photostimulation, Siberian hamsters were placed in short days (6:18-h light-dark) at 3 (experiment 1) or 6 (experiment 2) wk of age where they were held for 3 (experiment 1) or 4 (experiment 2) wk. Hamsters were then moved to long photoperiod (16:8-h light-dark). In experiment 1, brains were collected 1-21 days after transfer from short to long days. In experiment 2, brains were collected only on the second morning of long day exposure. Long and short day controls were included in both experiments. Cells containing GnRH mRNA, as visualized by in situ hybridization, were counted. As expected, there were no differences in the number of detectable GnRH mRNA-containing cells among animals chronically exposed to long or short photoperiods. However, on the second morning after transfer from short to long photoperiod, a positive shift in the distribution of GnRH mRNA-containing cells occurred relative to the respective controls in the two experiments. Increases in follicle-stimulating hormone secretion and gonadal growth occurred days later. In conclusion, a rapid but transient increase in the distribution of detectable GnRH mRNA-cont...Continue Reading

References

Dec 1, 1979·The Journal of Endocrinology·G E Pickard, A J Silverman
Jan 1, 1986·Proceedings of the National Academy of Sciences of the United States of America·J P AdelmanP H Seeburg
Jan 1, 1985·Neuroscience and Biobehavioral Reviews·R W StegerA Bartke
Mar 1, 1984·The Journal of Experimental Zoology·R W StegerF Talamantes
Sep 1, 1982·Journal of Reproduction and Fertility·S M SimpsonD H Ellis

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Related Feeds

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.